| Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain |
|
| 08:30 - 08:50 | Altered pathways and target therapies in MDS Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain |
| 08:50 - 09:10 | Treatment of CCUS Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA |
| 09:10 - 09:25 | Discussion |
| Chairs: Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 09:25 - 09:45 | New developments in the management of myelofibrosis Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain |
| 09:45 - 10:05 | Management of advanced stage chronic myeloid leukaemia Dr. Guillermo Ortí, Hospital Universitario Vall d'Hebron, Barcelona, Spain |
| 10:05 - 10:25 | aCML and CNL. Diagnostic approach and treatment Dr. Gonzalo Carreño, Hospital Universitario 12 de Octubre, Madrid, Spain |
| 10:25 - 10:40 | Discussion |
| Chair: Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 11:10 - 11:30 | Driver mutations and immune microenvironment in AML Dr. Antonio Curti, Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bolonia, Italy |
| 11:30 - 11:50 | Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia Dr. Charles Craddock, Queen Elizabeth Hospital Birmingham, London, UK |
| 11:50 - 12:10 | Integration of immunotherapy into frontline Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA |
| 12:10 - 12:25 | Discussion |
| 12:25 - 12:45 | Targeting IDH 2 Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
| 12:45 - 13:05 | FLT 3 Optimal approaches to frontline FLT3 mutated AML Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy |
| 13:05 - 13:20 | Discussion |
| Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 14:00 - 14:15 | An update on data for the mIDH1 AML population Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA |
| 14:15 - 14:30 | Testing in time Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain |
| 14:30 - 14:45 | Case study Dr. Susana Vives, Institut Català d'Oncologia, Badalona, Barcelona, Spain |
| 14:45 - 15:00 | Questions and Answers |
| Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain |
|
| 15:00 - 15:15 | Monoclonals and CAR-T in ALL Dr. Luis Madero, Hospital Universitario Quirónsalud, Madrid, Spain |
| 15:15 - 15:30 | Prevention and management of toxicities in ALL Dr. David Díaz, Hospital Universitario Infantil Niño Jesús Madrid, Spain |
| Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain |
|
| 15:30 - 16:00 | VEN+HMA : long term outcomes, who does the best Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA |
| 16:00 - 16:30 | Venetoclax combination for AML patients and Real world data Dr. Yakir Moshe, Tel Aviv Sourasky Medical Center - Ichilov, Tel Aviv, Israel |
| 16:30 - 16:45 | Discussion |
| Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
| Dr. Felipe Casado, Hospital General Universitario de Toledo, Spain |
| Chairs: Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy |
|
| 18:15 – 18:45 | What to do after 1 CR in patients between 65 al 75 yo? An open discussion of options Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain |
| Chairs: Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 18:45 - 19:05 | Graft versus host (GVH) disease and leukemia free survival, can we achieve this? Dr. Javier Bolaños, Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins, Baltimore, USA |
| 19:05 - 19:25 | AML with 10-20% blasts, induction or direct HSCT? Options Dr. David Valcárcel, Institute of Oncology, Hospital Quirónsalud Barcelona, Spain |
| 19:25 - 19:45 | Immune based approaches in AML: CART, NK cell, bispecificsmoving to the next chapter Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA |
| 19:45 - 20:00 | Discussion |